stockrowDianthus Therapeutics, Inc.
DNTH Healthcare Biotechnology
Dianthus Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 million, down 67.3% from fiscal 2024.
- Revenue
- +205.6%
- EPS
- +16.1%
- Free cash flow
- −65.9%
Quarter to September 2026, against a year earlier
Follow DNTH
Alert me
Dianthus Therapeutics, Inc. (DNTH) Return on assets
Dianthus Therapeutics, Inc.'s return on assets over the twelve months to 30 September 2026 was −21.8%, up 14.1 percentage points from fiscal 2025 (−35.9%). Over the past ten years it has ranged from −107.9% (fiscal 2017) to −20.9% (fiscal 2022); the current reading is higher than 60% of that period. That is above the Biotechnology industry median of −46.1% and above the Healthcare sector median of −29.5%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −35.9% | (5.17) |
| FY2024 | −30.7% | 2.47 |
| FY2023 | −33.2% | (12.32) |
| FY2022 | −20.9% | 19.61 |
| FY2021 | −40.5% | 5.91 |
| FY2020 | −46.4% | 1.78 |
| FY2019 | −48.2% | 6.24 |
| FY2018 | −54.4% | 53.52 |
| FY2017 | −107.9% | (78.33) |
| FY2016 | −29.6% | — |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| EWTX Edgewise Therapeutics, Inc. compare | 85.4% |
| LEGN Legend Biotech Corporation Sponsored ADR compare | −5.32% |
| TVTX Travere Therapeutics, Inc. compare | −17.5% |
| CRSP CRISPR Therapeutics AG compare | −19.0% |
| MANE Veradermics Incorporated compare | −20.9% |
| DNTH Dianthus Therapeutics, Inc. | −21.8% |
| DFTX Definium Therapeutics, Inc. compare | −51.4% |
| ERAS Erasca, Inc. compare | −65.3% |
| COGT Cogent Biosciences, Inc. compare | −68.0% |
| Biotechnology industry median | −46.1% |
| Healthcare sector median | −29.5% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on DNTH
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- Beneish M-score
- The full statement